蓝鸟生物收到凯雷集团和 SK 资本合伙公司更高的前期收购报价

新浪财经
Yesterday

蓝鸟生物(Bluebird bio)以及凯雷集团(Carlyle Group)和 SK 资本合伙公司(SK Capital Partners)周三表示,这两家私募股权公司已提出以每股 5 美元的前期报价收购这家基因疗法制造商。股东可以选择接受这一新报价,或者之前每股 3 美元的报价,若蓝鸟生物实现某些销售里程碑,还会额外获得每股 6.84 美元。责任编辑:郭明煜

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10